FIGURE 5.

HIF‐1α‐expressed fibroblasts secrete CCL5 to drive the growth of LC. A, By treatment of CM of MOCK cells and H1‐1 cells, the cell proliferation abilities of LLC cells were observed and measured. CCL5 receptor inhibitor TAK‐779 (10 nmol/L) was added in the condition mediums. The right column is the statistics of cell proliferation abilities at 70 h (n = 3). B, By treatment of CM of MOCK cells and H1‐1 cells, the cell clones of LLC were observed and measured. CCL5 receptor inhibitor TAK‐779 was added in the condition mediums (n = 3). C, The mRNA levels of Ccl2, Ccl5, Cxcl1, Egf, Igf1, Igf2, Il11 and Il6 were determined by real‐time PCR in the MOCK cells and H1‐1 cells treated with or without hypoxia (1% O₂) (n = 3). D, The protein p‐p65, p65, p‐STAT3 and STAT3 were determined by western blot in MOCK cells and H1‐1 cells which were treated with Cocl2 for 5 and 15 min. E, The secretion levels of CCL5 in the CM of MOCK cells and H1‐1 cells were analyzed by ELISA kit. NF‐kB inhibitor SC75741 (1 μmol/L) was added to inhibit the cellular NF‐kB signaling pathway (n = 3). (*P < 0.05, **P < 0.01, ***P < 0.001)